[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "The most likely diagnosis is Primary CNS Lymphoma (PCNSL).\n\nThis diagnosis is supported by:\n1. Low CD4 count (<100 cells/\u03bcL)\n2. Positive EBV DNA in CSF (strongly associated with PCNSL in HIV patients)\n3. MRI findings of a solitary, weakly ring-enhancing lesion in the corpus callosum\n4. Clinical symptoms: headaches, confusion, ataxia\n5. Subacute presentation over 2 weeks\n\nPCNSL in HIV patients is strongly associated with EBV infection and typically occurs in severely immunocompromised individuals with CD4 counts below 100 cells/\u03bcL, as seen in this patient.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "Enfuvirtide (T-20, brand name Fuzeon) is the medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It is a fusion inhibitor that prevents HIV from entering CD4+ T cells by binding to the gp41 subunit, thereby blocking the fusion of the viral and cellular membranes. However, it's important to note that enfuvirtide is not typically used as first-line therapy due to its need for twice-daily subcutaneous injections and is usually reserved for salvage therapy in treatment-experienced patients with multi-drug resistant HIV.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV screening test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Given the symptoms (fever, malaise, lymphadenopathy) and the relatively high CD4 count (650/mm3), this patient is most likely in the acute HIV infection stage, also known as acute retroviral syndrome or primary HIV infection. This typically occurs 2-4 weeks after initial HIV exposure and presents with flu-like symptoms. The CD4 count is still relatively preserved at this early stage, which supports this diagnosis.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 57-year-old HIV-positive male with a history of intravenous drug abuse presents to the emergency room complaining of arm swelling. He reports that he developed progressively worsening swelling and tenderness over the right antecubital fossa three days prior. He recently returned from a trip to Nicaragua. His past medical history is notable for an anaphylactoid reaction to vancomycin. His temperature is 101.4\u00b0F (38.6\u00b0C), blood pressure is 140/70 mmHg, pulse is 110/min, and respirations are 20/min. Physical examination reveals an erythematous, fluctuant, and tender mass overlying the right antecubital fossa. Multiple injection marks are noted across both upper extremities. He undergoes incision and drainage and is started on an antibiotic that targets the 50S ribosome. He is discharged with plans to follow up in one week. However, five days later he presents to the same emergency room complaining of abdominal cramps and watery diarrhea. What class of pathogens is most likely responsible for this patient\u2019s current symptoms?",
    "answer": "Given the clinical scenario, this patient most likely has Clostridioides difficile (C. diff) infection. Here's the reasoning:\n\n1. The patient was initially treated with what appears to be a macrolide or lincosamide antibiotic (targets 50S ribosome)\n2. He developed watery diarrhea and abdominal cramps within days of antibiotic treatment\n3. C. diff is a common complication of antibiotic therapy, especially in:\n   - Immunocompromised patients (HIV-positive)\n   - Those receiving broad-spectrum antibiotics\n   - Healthcare exposure (recent ER visit)\n\nC. diff is a gram-positive, spore-forming anaerobic bacterium that can proliferate in the gut when normal flora is disrupted by antibiotics. The infection typically presents with the symptoms described: watery diarrhea and abdominal cramps, usually developing within days to weeks of antibiotic exposure.\n\nAlternative diagnoses are possible but less likely given the clear temporal relationship with recent antibiotic use and the typical presentation.",
    "true_answer": "Gram-positive bacillus is most likely responsible for this patient\u2019s current symptoms."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "The most likely target would be gp120, which is a surface glycoprotein on the HIV envelope. \n\nThis is because:\n1. gp120 is exposed on the viral surface and accessible to antibodies\n2. It plays a crucial role in viral entry by binding to CD4 receptors\n3. It's one of the main targets of neutralizing antibodies in natural infection\n4. It's highly immunogenic and commonly detected in diagnostic tests\n\nThe accessibility and functional importance of gp120 make it an attractive target for therapeutic antibody development.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "The most likely causal organism is Aspergillus fumigatus. The clinical presentation (fever, hemoptysis), radiographic finding (fibrocavitary lesion), and most importantly, the microscopic finding of septate hyphae branching at acute angles (45-degree angles) are classic features of invasive pulmonary aspergillosis. This is particularly common in immunocompromised patients, including those with HIV/AIDS who have low CD4 counts.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "The greatest risk in this scenario is bone marrow suppression (myelosuppression), particularly because both zidovudine (AZT) and valganciclovir can cause this side effect. When used together, there's an additive risk of:\n\n1. Anemia\n2. Neutropenia\n3. Thrombocytopenia\n\nThis is particularly concerning because the patient already shows signs of illness and has evidence of blood loss from CMV colitis. The clinician should monitor complete blood counts closely and may need to consider modifying the antiretroviral regimen, potentially switching from zidovudine to an alternative agent if severe bone marrow suppression occurs.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "For an infant born to an HIV-positive mother, the most appropriate diagnostic test would be HIV DNA PCR testing, which should be performed at:\n- 14-21 days of life\n- 1-2 months\n- 4-6 months\n\nHIV antibody testing is NOT appropriate for newborns because maternal antibodies cross the placenta and can persist in the infant for up to 18 months, leading to false-positive results. The DNA PCR test directly detects the presence of viral genetic material, making it the most reliable early diagnostic test for infants born to HIV-positive mothers.\n\nMeanwhile, the mother should be started on antiretroviral therapy immediately to reduce the risk of maternal-to-child transmission.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "In this scenario, the most appropriate next steps are:\n\n1. Counsel the patient about the importance of partner notification and encourage him to disclose his HIV status to his wife, as she may have been exposed and needs testing.\n\n2. Inform the patient that while healthcare providers must maintain confidentiality under HIPAA, most states have laws requiring reporting of HIV cases to public health authorities.\n\n3. Explain that public health departments can assist with anonymous partner notification if the patient is unwilling to disclose directly.\n\n4. If the patient continues to refuse to inform his wife, the physician should consult their state's specific laws regarding HIV disclosure and partner notification, as some states permit or require physicians to notify known sexual partners who are at risk.\n\nThe key is balancing patient confidentiality with the ethical and legal obligation to protect public health and prevent harm to others. While HIV status is protected health information, there may be legal provisions allowing disclosure to protect at-risk partners.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the clinical presentation and laboratory findings, this patient has acute pancreatitis. The most likely etiology in this case is medication-induced pancreatitis, specifically from antiretroviral therapy (ART).\n\nKey points supporting this conclusion:\n1. Patient is on HIV medications (though unable to recall names)\n2. Several antiretroviral medications, particularly didanosine, stavudine, and less commonly other NRTIs, are known to cause pancreatitis\n3. Normal gallbladder on CT (ruling out gallstone pancreatitis)\n4. Only \"moderate\" alcohol use reported (making alcoholic pancreatitis less likely)\n5. CT findings and elevated lipase/amylase confirm pancreatitis diagnosis\n\nThe clinician should:\n1. Obtain a detailed medication history\n2. Review the specific ART regimen\n3. Consider temporary discontinuation of the offending medication in consultation with an HIV specialist\n4. Consider alternative ART options if medication-induced pancreatitis is confirmed",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " What would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?",
    "answer": "For studying microRNAs as therapeutic targets in HIV patients, I would recommend this step-wise approach:\n\n1. Initial screening:\n- Perform RNA sequencing to identify differentially expressed miRNAs in HIV+ vs. healthy controls\n- Focus on miRNAs involved in viral replication and immune response\n\n2. Validation studies:\n- qRT-PCR validation of candidate miRNAs\n- Cell culture experiments using relevant immune cell types (CD4+ T cells)\n\n3. Functional studies:\n- Use miRNA mimics and inhibitors to confirm direct effects\n- Evaluate impact on viral replication and immune function\n- Identify specific target genes and pathways\n\n4. Clinical correlation:\n- Analyze relationships between miRNA levels and clinical parameters\n- Study associations with viral load and CD4 counts\n\n5. Therapeutic potential:\n- Test delivery methods for miRNA-based therapeutics\n- Evaluate safety and efficacy in animal models before human trials\n\nThe key is to establish clear causality between miRNA changes and HIV pathogenesis before moving to therapeutic development.",
    "true_answer": "To study microRNAs as therapeutic targets in HIV patients, the best methodological approach would likely include a combination of in vitro experiments, in vivo animal models, and clinical trials . Initial in vitro experiments would involve the use of HIV-infected cell lines or primary cells to study the function and expression of specific microRNAs in relation to HIV replication and pathogenesis . This research would provide insights into the potential roles of microRNAs in HIV infection and help identify candidate microRNAs for therapeutic targeting . Next, in vivo animal models, such as humanized mice, should be employed to study the effects of modulating specific microRNAs on HIV infection and disease progression . These models would help evaluate the safety and efficacy of potential microRNA-based therapies, as well as investigate the potential for off-target effects and immunogenicity . Techniques such as delivery of microRNA mimics or antagomirs, viral vector-mediated overexpression or knockdown, and CRISPR-Cas9 editing can be used to manipulate microRNA expression in these models  . Finally, clinical trials should be conducted to validate the safety, efficacy, and tolerability of potential microRNA-based therapies in HIV patients . These trials would involve the enrollment of HIV-positive patients to receive the experimental treatment(s) under controlled conditions, with rigorous monitoring of viral load, treatment-related adverse events, immune function, and other relevant parameters . The results of these clinical trials would be instrumental in determining the clinical feasibility of microRNA-based therapies for treating HIV infections ."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "DNA methylation changes have been observed in HIV infection, though our understanding is still evolving. In latent HIV-1, increased methylation of the viral promoter region (5' LTR) is associated with viral silencing and maintenance of latency. During active infection, global DNA methylation patterns in host cells are altered, with studies showing both hyper- and hypomethylation of various genes involved in immune response and inflammation. However, detailed methylation profiles and their full clinical significance are still under investigation, and more research is needed to fully understand these epigenetic changes.",
    "true_answer": "According to the scientific literature, DNA methylation significantly influences HIV-1 pathogenesis. In active infection, global changes in host cell DNA methylation are evident, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]